Drug-Eluting Balloon Market Size, Trends and Growth Analysis by 2027

The global market for drug-eluting balloons is projected to grow significantly, reaching approximately US$ 1,870.60 million by 2027, up from US$ 516.65 million in 2018. This growth represents a compound annual growth rate (CAGR) of 15.6% from 2019 to 2027.

Several key factors are driving this market expansion, including a notable rise in the incidence of vascular diseases, continuous innovations in product development, and an increasing elderly population. However, the market may experience slower growth due to the high costs associated with procedures and products, as well as stringent regulatory requirements for product approval throughout the forecast period.

The drug-eluting balloon market features a mix of established leaders and emerging companies. Prominent players include Medtronic plc, Boston Scientific Corporation, Cook Medical, and Royal Philips, which is part of Koninklijke Philips N.V. These companies are actively involved in the ongoing development of various medical devices, enhancing their offerings to maintain competitiveness in the global arena. For example, in November 2019, Medtronic obtained approval from the US Food and Drug Administration (FDA) for its In.Pact AV drug-coated balloon, designed for treating failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) who are undergoing dialysis. Similarly, Royal Philips introduced two new additions to its Stellarex portfolio, specifically 0.035-inch low-dose drug-coated balloons measuring 200mm and 150mm, which have also received FDA approval for treating de novo and restenotic lesions in the native superficial femoral or popliteal arteries in the upper legs.

The introduction of such innovative products by both market leaders and new entrants is a significant factor propelling the growth of the drug-eluting balloon market. This surge in product offerings is largely due to the expanded treatment options available for healthcare providers addressing peripheral artery diseases (PADs), cardiovascular issues, and renal artery conditions, among others.

The drug-eluting balloon market is categorized based on product type and end user. The product type segment includes coronary drug-eluting balloons, peripheral drug-eluting balloons, and other related products. In terms of end users, the market is divided into hospitals, catheterization laboratories and cardiac centers, as well as ambulatory surgical centers.